
    
      This is a Phase 2, double-blind, placebo-controlled, parallel-group, multicenter study to
      evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SUVN-G3031 compared
      to placebo in participants with narcolepsy with and without cataplexy. Participants will be
      randomized at a ratio of 1:1:1 to 2 mg SUVN-G3031, 4 mg SUVN-G3031, or placebo. Each
      participant will receive study drug once daily, in a tablet formulation, for 14 days. Enough
      participants will be screened to enable 114 patients to be enrolled (38 per treatment group).
    
  